Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Onesource Specialty Pharma Ltd. (ONESOURCE.NS)
Bengaluru, IN
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | +1.60% | +20.80% | +44.35% | +4.19% | +2.70% | +14.17% | +8.77% | +8.77% | +8.77% | +8.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%-1.6% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-33,617.3% Q1'26: -95.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-25.0% Q1'26: -86.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+1.8% ★ Q1'26: +4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+0.4% ★ Q1'26: +0.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.8% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.94× Q1'26: 4.09× (vs Q1'25)
| Metric |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 3 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|
| Revenue |
14.45B
est: 14.45B (0.0%)
|
13.41B
12.61B – 13.72B
-7.2% YoY
|
22.30B
20.28B – 24.18B
+66.3% YoY
|
33.91B
30.16B – 36.13B
+52.1% YoY
|
| EBITDA |
3.61B
est: 3.35B (+7.7%)
|
3.11B
2.92B – 3.18B
-7.2% YoY
|
5.17B
4.70B – 5.61B
+66.3% YoY
|
7.87B
6.99B – 8.38B
+52.1% YoY
|
| EBIT |
870.75M
est: 563.09M (+54.6%)
|
522.76M
491.50M – 534.65M
-7.2% YoY
|
869.21M
790.44M – 942.21M
+66.3% YoY
|
1.32B
1.18B – 1.41B
+52.1% YoY
|
| Net Income |
-2.10M
est: 2.19B (-100.1%)
|
-738.03M
-1.10B – 555.00M
-133.7% YoY
|
3.99B
3.00B – 4.84B
+641.0% YoY
|
8.31B
7.14B – 9.76B
+108.2% YoY
|
| SGA |
1.17B
est: 2.77B (-57.8%)
|
2.57B
2.42B – 2.63B
-7.2% YoY
|
4.28B
3.89B – 4.64B
+66.3% YoY
|
6.51B
5.79B – 6.93B
+52.1% YoY
|
| EPS |
-0.02
est: 19.10 (-100.1%)
|
-2.83
-9.57 – 4.84
-114.8% YoY
|
36.10
26.21 – 42.21
+1,377.9% YoY
|
74.58
62.30 – 85.17
+106.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI India Small-Cap ETF SMIN | 0.29% | 2.08M | 0.74% |
| 2 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.06% | 200.5K | 0.74% |
| 3 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.06% | 345.5K | 0.55% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 182.8K | 0.72% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 3.32M | 0.06% |
| 6 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 31.9K | 0.33% |
| 7 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 14.9K | 0.42% |
| 8 | Avantis Emerging Markets Value ETF AVES | 0.01% | 133.6K | 0.36% |
| 9 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.01% | 269.2K | 0.28% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 257.0K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Neeraj Sharma | Chief Executive Officer, MD & Director | 7M | male |
| Anurag Bhagania | Chief Financial Officer | — | male |
| Arun Kumar Pillai | Founder & Non-Executive Director | — | male |
| Bernhard Thurnbauer | Chief Quality Officer | — | male |
| Biju Mathew | Chief Operating Officer | — | male |
| Jeffrey Wong | Chief Business Officer | — | male |
| Milan Doshi | Senior Vice President of Global BD | — | male |
| Prateek Gupta | Senior Vice President & Head of Technical Development | — | — |
| Allada Trisha | Company Secretary & Compliance officer | — | female |
| Ravi Kumar | Global Head of Injectables and Head of Corporate Strategy, Portfolio & SPO | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONESOURCE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
